THE CHALLENGE
Treating chronic inflammatory and cardiovascular diseases like atherosclerosis has proven difficult due to the lack of precision in current therapies. While these conditions are driven by complex immune responses, existing treatments rely heavily on broad, systemic anti-inflammatory drugs that often come with unwanted side effects and limited effectiveness. These therapies are not designed to specifically target the immune cells that cause the most harm, making it difficult to stop disease progression at its root. This creates a major gap in the market for more targeted, efficient, and safer therapies that can better manage these widespread health issues. Developing such solutions not only addresses a significant medical need but also presents a strong business opportunity in a global market urgently seeking more effective ways to manage chronic inflammation and cardiovascular risk.
OUR SOLUTION
We offer a groundbreaking approach to treating chronic inflammatory and cardiovascular diseases by creating a targeted, cell-based therapy that addresses the root causes of inflammation. Instead of relying on traditional drugs that affect the whole body and often cause side effects, we isolate specific immune cells from donor blood and reprogram them to become naturally anti-inflammatory. This process transforms harmful cells into protective ones, helping to reduce tissue damage and plaque buildup in blood vessels. With a focus on precision and safety, this therapy has the potential to be more effective and longer-lasting than current treatments. It taps into a large and growing market with an urgent need for innovative, next-generation therapies that can offer real improvements in patient outcomes while reducing healthcare costs over time.
Single cell RNA sequencing (scRNAseq) analyses of murine neutrophils showing differentially expressed genes, revealing the nature of anti-inflammatory, resolving neutrophils capable of reducing inflammation and improving tissue homeostasis/function. Purified naïve mouse bone marrow cultured in the presence of G-CSF (100ng/ml) were used to perform single cell sequencing. Differentially expressed genes were identified in the above bubble plot.
Advantages:
Potential Application: